Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
9 "Therapeutics"
Filter
Filter
Article type
Keywords
Publication year
Authors
Funded articles
Review Articles
Calcium & bone metabolism
Treatment of Hypoparathyroidism by Re-Establishing the Effects of Parathyroid Hormone
Lars Rejnmark
Endocrinol Metab. 2024;39(2):262-266.   Published online April 4, 2024
DOI: https://doi.org/10.3803/EnM.2024.1916
  • 1,884 View
  • 126 Download
  • 1 Crossref
AbstractAbstract PDFPubReader   ePub   
The conventional treatment of hypoparathyroidism (HypoPT) includes active vitamin D and calcium. Despite normalization of calcium levels, the conventional treatment is associated with fluctuations in calcium levels, hypercalciuria, renal impairment, and decreased quality of life (QoL). Replacement therapy with parathyroid hormone (PTH)(1-84) is an option in some countries. However, convincing beneficial effects have not been demonstrated, which may be due to the short duration of action of this treatment. Recently, palopegteriparatide (also known as TransCon PTH) has been marketed in Europe and is expected also to be approved in other countries. Palopegteriparatide is a prodrug with sustained release of PTH(1-34) designed to provide stable physiological PTH levels for 24 hours/day. A phase 3 study demonstrated maintenance of normocalcemia in patients with chronic HypoPT, with no need for conventional therapy. Furthermore, this treatment lowers urinary calcium and improves QoL. Another long-acting PTH analog with effects on the parathyroid hormone receptor (eneboparatide) is currently being tested in a phase 3 trial. Furthermore, the treatment of autosomal dominant hypocalcemia type 1 with a calcilytic (encaleret) is also being tested. All in all, improved treatment options are on the way that will likely take the treatment of HypoPT to the next level.

Citations

Citations to this article as recorded by  
  • Hypoparathyroidism update
    Cherie Chiang
    Current Opinion in Endocrinology, Diabetes & Obesity.2024;[Epub]     CrossRef
Close layer
Diabetes, Obesity and Metabolism
Overcoming Therapeutic Inertia as the Achilles’ Heel for Improving Suboptimal Diabetes Care: An Integrative Review
Boon-How Chew, Barakatun-Nisak Mohd-Yusof, Pauline Siew Mei Lai, Kamlesh Khunti
Endocrinol Metab. 2023;38(1):34-42.   Published online February 16, 2023
DOI: https://doi.org/10.3803/EnM.2022.1649
  • 3,378 View
  • 235 Download
  • 2 Web of Science
  • 2 Crossref
AbstractAbstract PDFPubReader   ePub   
The ultimate purpose of diabetes care is achieving the outcomes that patients regard as important throughout the life course. Despite advances in pharmaceuticals, nutraceuticals, psychoeducational programs, information technologies, and digital health, the levels of treatment target achievement in people with diabetes mellitus (DM) have remained suboptimal. This clinical care of people with DM is highly challenging, complex, costly, and confounded for patients, physicians, and healthcare systems. One key underlying problem is clinical inertia in general and therapeutic inertia (TI) in particular. TI refers to healthcare providers’ failure to modify therapy appropriately when treatment goals are not met. TI therefore relates to the prescribing decisions made by healthcare professionals, such as doctors, nurses, and pharmacists. The known causes of TI include factors at the level of the physician (50%), patient (30%), and health system (20%). Although TI is often multifactorial, the literature suggests that 28% of strategies are targeted at multiple levels of causes, 38% at the patient level, 26% at the healthcare professional level, and only 8% at the healthcare system level. The most effective interventions against TI are shorter intervals until revisit appointments and empowering nurses, diabetes educators, and pharmacists to review treatments and modify prescriptions.

Citations

Citations to this article as recorded by  
  • Obesity management from the perspectives of people living with obesity in Canada: A mixed‐methods study
    David C. W. Lau, Ian Patton, Reena Lavji, Adel Belloum, Ginnie Ng, Renuca Modi
    Diabetes, Obesity and Metabolism.2024; 26(4): 1529.     CrossRef
  • Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?
    André J Scheen
    Expert Review of Clinical Pharmacology.2023; 16(11): 1053.     CrossRef
Close layer
Diabetes, Obesity and Metabolism
State-of-the-Art Overview of the Pharmacological Treatment of Non-Alcoholic Steatohepatitis
Yongin Cho, Yong-ho Lee
Endocrinol Metab. 2022;37(1):38-52.   Published online February 28, 2022
DOI: https://doi.org/10.3803/EnM.2022.102
  • 4,566 View
  • 287 Download
  • 3 Web of Science
  • 4 Crossref
AbstractAbstract PDFPubReader   ePub   
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide, and non-alcoholic steatohepatitis (NASH), a subtype of NAFLD, can progress to cirrhosis, hepatocellular carcinoma, and death. Nevertheless, the current treatment for NAFLD/NASH is limited to lifestyle modifications, and no drugs are currently officially approved as treatments for NASH. Many global pharmaceutical companies are pursuing the development of medications for the treatment of NASH, and results from phase 2 and 3 clinical trials have been published in recent years. Here, we review data from these recent clinical trials and reports on the efficacy of newly developed antidiabetic drugs in NASH treatment.

Citations

Citations to this article as recorded by  
  • Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study
    Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
    BMJ.2024; : e076388.     CrossRef
  • Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
    Inha Jung, Dae-Jeong Koo, Won-Young Lee
    Diabetes & Metabolism Journal.2024; 48(3): 327.     CrossRef
  • Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Soyeon Shin, Jaeyoung Kim, Ju Yeon Lee, Jun Kim, Chang-Myung Oh
    Journal of Obesity & Metabolic Syndrome.2023; 32(4): 289.     CrossRef
  • Sodium-glucose cotransporter 2 inhibitors for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: A nationwide propensity-score matched cohort study
    Jinyoung Kim, Kyungdo Han, Bongsung Kim, Ki-Hyun Baek, Ki-Ho Song, Mee Kyoung Kim, Hyuk-Sang Kwon
    Diabetes Research and Clinical Practice.2022; 194: 110187.     CrossRef
Close layer
Bone Metabolism
Update on Glucocorticoid Induced Osteoporosis
Soo-Kyung Cho, Yoon-Kyoung Sung
Endocrinol Metab. 2021;36(3):536-543.   Published online June 1, 2021
DOI: https://doi.org/10.3803/EnM.2021.1021
  • 5,474 View
  • 365 Download
  • 8 Web of Science
  • 9 Crossref
AbstractAbstract PDFPubReader   ePub   
Glucocorticoids are used to treat many autoimmune and inflammatory diseases. However, an adverse systemic effect is a deleterious effect on bone, which may lead to glucocorticoid-induced osteoporosis, characterized by a rapid and transient increase in bone resorption and fracture risk, which may increase rapidly within 3 months of commencing oral glucocorticoids. Therefore, early risk assessment and intervention are crucial for preventing fractures in patients receiving glucocorticoids. Recent practice guidelines recommend an assessment for fracture risk in patients beginning or receiving glucocorticoids for more than 3 months, and they have suggested fracture risk assessment tool values for identifying patients who need preventive treatment. Bisphosphonates are currently the recommended first-line therapy for the prevention and treatment of glucocorticoid-induced osteoporosis. These have been shown to increase the bone mineral density in the spine and hip and to decrease the incidence of vertebral fractures. Recently, a more potent antiresorptive agent, denosumab, has been shown to increase the bone density in patients receiving glucocorticoids. Teriparatide has been shown to have a preventive effect on vertebral fractures, but not on nonvertebral fractures. In this article we aimed to provide an update on glucocorticoid-induced osteoporosis by focusing on the assessment of its risk and treatment options.

Citations

Citations to this article as recorded by  
  • Protective role of 3-oxypyridine derivatives in rats’ steroid-induced osteoporosis associated with reduced oxidative stress and recovery of nitric oxide formation
    A. P. Danilenko, K. S. Trunov, M. V. Pokrovsky, L. M. Danilenko, M. V. Korokin, O. S. Gudyrev, A. A. Khentov, N. P. Masalytina, I. A. Tatarenkova, A. V. Cherednichenko, E. V. Boeva, I. S. Koklin, E. I. Taran
    Pharmacy & Pharmacology.2023; 11(1): 48.     CrossRef
  • Guía de práctica clínica para la prevención, el diagnóstico y el tratamiento de la osteoporosis inducida por glucocorticoides. Asociación Colombiana de Reumatología, 2023
    Monique Chalem, Noemi Casas, Aura María Domínguez, Daniel Gerardo Fernández, Andrés González, Edwin Jáuregui, José Fernando Molina, Diana Nathalie Rincón, Carlos Enrique Toro-Gutiérrez, Francisco Juan Vargas Grajales, Susan Martínez, Linda Ibatá
    Revista Colombiana de Reumatología.2023;[Epub]     CrossRef
  • Influence of Piper sarmentosum Aqueous Extract on the Expression of Osteocalcin in Glucocorticoid-induced Osteoporotic Rats
    Elvy Suhana Mohd Ramli, Ima Nirwana Soelaiman, Suryati Mohd Thani, Nurul Huda Mohd Nor, Nurul Hayati Mohamad Zainal, Siti Saleha Masrudin, Siti Fadziyah Mohamad Asri
    Malaysian Journal of Medicine and Health Sciences.2023; 19(s12): 115.     CrossRef
  • Vitamin D Supplementation in Patients with Juvenile Idiopathic Arthritis
    Chao-Yi Wu, Huang-Yu Yang, Shue-Fen Luo, Jing-Long Huang, Jenn-Haung Lai
    Nutrients.2022; 14(8): 1538.     CrossRef
  • A Review on the Molecular Mechanisms of Action of Natural Products in Preventing Bone Diseases
    Innocent U. Okagu, Timothy P. C. Ezeorba, Rita N. Aguchem, Ikenna C. Ohanenye, Emmanuel C. Aham, Sunday N. Okafor, Carlotta Bollati, Carmen Lammi
    International Journal of Molecular Sciences.2022; 23(15): 8468.     CrossRef
  • Antiosteoporosis and bone protective effect of nimbolide in steroid‐induced osteoporosis rats
    Jiang Huo, Yu Ding, Xinyuan Wei, Qi Chen, Bin Zhao
    Journal of Biochemical and Molecular Toxicology.2022;[Epub]     CrossRef
  • Comparison of denosumab and oral bisphosphonates for the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis
    Lianghai Jiang, Jian Dong, Jianwei Wei, Lantao Liu
    BMC Musculoskeletal Disorders.2022;[Epub]     CrossRef
  • Improvement in Glucocorticoid-Induced Osteoporosis on Switching from Bisphosphonates to Once-Weekly Teriparatide: A Randomized Open-Label Trial
    Toshihiro Nanki, Mai Kawazoe, Kiyoko Uno, Wataru Hirose, Hiroaki Dobashi, Hiroshi Kataoka, Toshihide Mimura, Hiroshi Hagino, Hajime Kono
    Journal of Clinical Medicine.2022; 12(1): 292.     CrossRef
  • Understanding of Glucocorticoid Induced Osteoporosis
    Chang-Nam Son
    Keimyung Medical Journal.2021; 40(2): 69.     CrossRef
Close layer
Bone Metabolism
Operationalizing Treat-to-Target for Osteoporosis
E. Michael Lewiecki
Endocrinol Metab. 2021;36(2):270-278.   Published online March 24, 2021
DOI: https://doi.org/10.3803/EnM.2021.970
  • 5,881 View
  • 306 Download
  • 5 Web of Science
  • 5 Crossref
AbstractAbstract PDFPubReader   ePub   
Treat-to-target (TTT) for osteoporosis is a concept for individualizing patient treatment decisions that focuses on achieving an acceptable level of fracture risk rather than response to treatment alone. While a response to treatment is essential in order to achieve an acceptable level of risk, it is not necessarily sufficient. Some patients have a good response to treatment yet remain at high level of fracture risk. Since there is no way to directly measure bone strength in patients treated for osteoporosis, a surrogate measurement must be used. Bone mineral density (BMD) is commonly used to select patients for treatment and has emerged as the most useful surrogate for assessing reduction of fracture risk after treatment is started. Recent large meta-regression studies have shown a robust correlation between larger increases in BMD with treatment and greater reductions in fracture risk. Application of TTT for osteoporosis involves assessing fracture risk before starting treatment and initiating treatment with an agent that is most likely to reduce fracture risk to an acceptable level, represented by a target BMD T-score, over a reasonable period of time. This review offers suggestions for implementing TTT for osteoporosis in clinical practice and managing patients who fail or succeed in reaching the target. More study is needed to fully validate the use of TTT for osteoporosis for initiating and modifying treatments to reduce fracture risk.

Citations

Citations to this article as recorded by  
  • Treatment sequencing using the dual amylin and calcitonin receptor agonist KBP-336 and semaglutide results in durable weight loss
    Anna Thorsø Larsen, Morten A. Karsdal, Kim Henriksen
    European Journal of Pharmacology.2023; 954: 175837.     CrossRef
  • Osteoporosis: Spotlight on current approaches to pharmacological treatment
    Dilşad Sindel
    Turkish Journal of Physical Medicine and Rehabilitation.2023; 69(2): 140.     CrossRef
  • Postmenopausal Osteoporosis
    Caren G. Solomon, Marcella Donovan Walker, Elizabeth Shane
    New England Journal of Medicine.2023; 389(21): 1979.     CrossRef
  • Prevalence and Risk Factors of T-Score Spine-Hip Discordance in Patients with Osteoporotic Vertebral Compression Fracture
    Byung-Ho Yoon, Ho Won Kang, Su Min Kim, Young Do Koh
    Journal of Bone Metabolism.2022; 29(1): 43.     CrossRef
  • Pharmacological treatment of osteoporosis: 2022 update
    Yunkyung Jeon, In-Joo Kim
    Journal of the Korean Medical Association.2022; 65(4): 241.     CrossRef
Close layer
Thyroid
Best Achievements in Clinical Thyroidology in 2020
Eun Kyung Lee, Young Joo Park
Endocrinol Metab. 2021;36(1):30-35.   Published online February 24, 2021
DOI: https://doi.org/10.3803/EnM.2021.103
  • 4,738 View
  • 249 Download
  • 3 Web of Science
  • 3 Crossref
AbstractAbstract PDFPubReader   ePub   
This review highlights the most interesting research in thyroidology conducted in 2020. The publications of interest discussed below dealt with the following topics: thyroid dysfunction, risk of thyroid cancer, molecular diagnostics and new therapeutics for thyroid cancer, and thyroid disease in the coronavirus disease 2019 pandemic era.

Citations

Citations to this article as recorded by  
  • Compensation for iodine deficiency conditions with drugs based on duckweed substrate
    M. Kh. Sadulaev, M. I. Usmanova, T. T. Tataev, A. M. Inderbiev, A. S.-A. Zhamalullayla, A. Salamova
    BIO Web of Conferences.2023; 76: 03002.     CrossRef
  • Use of long non-coding RNAs for the molecular diagnosis of papillary thyroid cancer
    Daham Kim, Juyeon Yu, Jiwon Kim, Yoon-a Hwang, Jin Kyong Kim, Cheol Ryong Ku, Jung Hyun Yoon, Jin Young Kwak, Kee-Hyun Nam, Eun Jig Lee
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Ultrasound-Guided Fine-Needle Aspiration with or without Negative Pressure for Different Types of Thyroid Nodules
    Qi Zhou, Wenjun Wu, Fang Wang, Xiaohua Gong, Xiaojun Chen
    International Journal of General Medicine.2021; Volume 14: 5475.     CrossRef
Close layer
Original Articles
Clinical Study
Trends in the Diagnosis and Treatment of Patients with Medullary Thyroid Carcinoma in Korea
Hwa Young Ahn, Jae Eun Chae, Hyemi Moon, Junghyun Noh, Young Joo Park, Sin Gon Kim
Endocrinol Metab. 2020;35(4):811-819.   Published online November 20, 2020
DOI: https://doi.org/10.3803/EnM.2020.709
  • 6,526 View
  • 197 Download
  • 13 Web of Science
  • 13 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Thyroid cancer is becoming increasingly common worldwide, but little is known about the epidemiology of medullary thyroid carcinoma (MTC). This study investigated the current status of the incidence and treatment of MTC using Korean National Health Insurance Service (NHIS) data for the entire Korean population from 2004 to 2016.
Methods
This study included 1,790 MTC patients identified from the NHIS database.
Results
The age-standardized incidence rate showed a slightly decreasing or stationary trend during the period, from 0.25 per 100,000 persons in 2004 to 0.19 in 2016. The average proportion of MTC among all thyroid cancers was 0.5%. For initial surgical treatment, 65.4% of patients underwent total thyroidectomy. After surgery, external-beam radiation therapy (EBRT) was performed in 10% of patients, a proportion that increased from 6.7% in 2004 to 11.0% in 2016. Reoperations were performed in 2.7% of patients (n=49) at a median of 1.9 years of follow-up (interquartile range, 1.2 to 3.4). Since November 2015, 25 (1.4%) patients with MTC were prescribed vandetanib by December 2016.
Conclusion
The incidence of MTC decreased slightly with time, and the proportion of patients who underwent total thyroidectomy was about 65%. EBRT, reoperation, and tyrosine kinase inhibitor therapy are additional treatments after initial surgery for advanced MTC in Korea.

Citations

Citations to this article as recorded by  
  • Big Data Research in the Field of Endocrine Diseases Using the Korean National Health Information Database
    Sun Wook Cho, Jung Hee Kim, Han Seok Choi, Hwa Young Ahn, Mee Kyoung Kim, Eun Jung Rhee
    Endocrinology and Metabolism.2023; 38(1): 10.     CrossRef
  • Update on C-Cell Neuroendocrine Neoplasm: Prognostic and Predictive Histopathologic and Molecular Features of Medullary Thyroid Carcinoma
    Chan Kwon Jung, Shipra Agarwal, Jen-Fan Hang, Dong-Jun Lim, Andrey Bychkov, Ozgur Mete
    Endocrine Pathology.2023; 34(1): 1.     CrossRef
  • Mouse Models to Examine Differentiated Thyroid Cancer Pathogenesis: Recent Updates
    Hye Choi, Kwangsoon Kim
    International Journal of Molecular Sciences.2023; 24(13): 11138.     CrossRef
  • Partial preservation of the normal thyroid gland based on tumor diameter may be possible in small medullary thyroid carcinoma: a two-center 15-year retrospective study
    Guiming Fu, Xiaoyi Li, Fengli Guo, Xianhui Ruan, Wei Zhang, Weijing Zhang, Yaping Zhang, Yibo Chen, Chunhua Li, Jin Chen, Xiangqian Zheng, Zhaohui Wang, Ming Gao
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Association of Socioeconomic Status With Long-Term Outcome in Survivors After Out-of-Hospital Cardiac Arrest: Nationwide Population-Based Longitudinal Study
    Kyung Hun Yoo, Yongil Cho, Jaehoon Oh, Juncheol Lee, Byuk Sung Ko, Hyunggoo Kang, Tae Ho Lim, Sang Hwan Lee
    JMIR Public Health and Surveillance.2023; 9: e47156.     CrossRef
  • Preoperative identification of low-risk medullary thyroid carcinoma: potential application to reduce total thyroidectomy
    Hyunju Park, Hyun Jin Ryu, Jung Heo, Man Ki Chung, Young Ik Son, Jung-Han Kim, Soo Yeon Hahn, Jung Hee Shin, Young Lyun Oh, Sun Wook Kim, Jae Hoon Chung, Jee Soo Kim, Tae Hyuk Kim
    Scientific Reports.2023;[Epub]     CrossRef
  • Clinical Characteristics, Surgical Management, and Prognostic Factors of Medullary Thyroid Carcinoma: A Retrospective, Single-Center Study
    Xin Wu, Binglu Li, Chaoji Zheng
    Technology in Cancer Research & Treatment.2022; 21: 153303382210784.     CrossRef
  • Understanding and Utilizing Claim Data from the Korean National Health Insurance Service (NHIS) and Health Insurance Review & Assessment (HIRA) Database for Research
    Dae-Sung Kyoung, Hun-Sung Kim
    Journal of Lipid and Atherosclerosis.2022; 11(2): 103.     CrossRef
  • Unilateral Surgery for Medullary Thyroid Carcinoma: Seeking for Clinical Practice Guidelines
    Daqi Zhang, Carla Colombo, Hui Sun, Hoon Yub Kim, Antonella Pino, Simone De Leo, Giacomo Gazzano, Luca Persani, Gianlorenzo Dionigi, Laura Fugazzola
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Total thyroidectomy vs thyroid lobectomy for localized medullary thyroid cancer in adults: A propensity-matched survival analysis
    Weili Liang, Jinyuan Shi, Hui Zhang, Guixu Lv, Tiantian Wang, Yong Wang, Bin Lv, Luchuan Li, Qingdong Zeng, Lei Sheng
    Surgery.2022; 172(5): 1385.     CrossRef
  • Constitutive Cytomorphologic Features of Medullary Thyroid Carcinoma Using Different Staining Methods
    Chih-Yi Liu, Chien-Chin Chen, Andrey Bychkov, Shipra Agarwal, Yun Zhu, Jen-Fan Hang, Chiung-Ru Lai, Hee Young Na, So Yeon Park, Weiwei Li, Zhiyan Liu, Deepali Jain, Ayana Suzuki, Mitsuyoshi Hirokawa, Noel Chia, Min En Nga, Tikamporn Jitpasutham, Somboon K
    Diagnostics.2021; 11(8): 1396.     CrossRef
  • Metastatic Lymph Node Ratio for Predicting Recurrence in Medullary Thyroid Cancer
    Jinyoung Kim, Jun Park, Hyunju Park, Min Sun Choi, Hye Won Jang, Tae Hyuk Kim, Sun Wook Kim, Jae Hoon Chung
    Cancers.2021; 13(22): 5842.     CrossRef
  • A High Frequency of Lobectomy Instead of Total Thyroidectomy to Treat Medullary Thyroid Cancer in Korea: Data from the Korean National Health Insurance Service
    Sun Wook Cho
    Endocrinology and Metabolism.2020; 35(4): 784.     CrossRef
Close layer
Endocrine Research
Therapeutic Effect of a Novel Chimeric Molecule Targeting Both Somatostatin and Dopamine Receptors on Growth Hormone-Secreting Pituitary Adenomas
Jean Kim, Ju Hun Oh, Heather Harlem, Michael D. Culler, Cheol Ryong Ku, Eun Jig Lee
Endocrinol Metab. 2020;35(1):177-187.   Published online March 19, 2020
DOI: https://doi.org/10.3803/EnM.2020.35.1.177
  • 4,678 View
  • 107 Download
  • 4 Web of Science
  • 5 Crossref
AbstractAbstract PDFPubReader   ePub   
Background

Acromegaly is a rare disease primarily caused by growth hormone (GH)-secreting pituitary adenomas, and its treatment is costly. Moreover, some patients are unresponsive to treatment. Hence, there are increasing efforts to develop new drugs with improved effectiveness for this disease. BIM23B065 is a novel chimeric molecule that acts on both somatostatin and dopamine receptors. This study aimed to investigate the effects of BIM23B065 compared with those of a somatostatin receptor analog and a dopamine agonist.

Methods

The effects of BIM23B065 on the proliferation, GH and insulin-like growth factor-1 (IGF-1) levels, and extracellular signal-regulated kinase (ERK) 1/2 and cyclic AMP response element binding (CREB) phosphorylation of GH3 cells were investigated with MTS assay, enzyme-linked immunosorbent assay, and Western blotting, respectively. The dosage and treatment duration of BIM23B065 were tested in animal models of GH-secreting pituitary adenoma. The effect of BIM23B065 (3 mg/kg/day) on changes in IGF-1 levels before and after treatment was further investigated.

Results

In vitro, BIM23B065 treatment decreased GH release in the culture media and downregulated ERK 1/2 and CREB phosphorylation to 22% and 26%, respectively. In vivo, IGF-1 expression decreased to 50 % after 4 weeks of treatment with BIM23B065 using an osmotic pump implant. Moreover, magnetic resonance imaging results showed that the tumor size decreased significantly following treatment with BIM23B065 for 4 weeks.

Conclusion

The novel chimeric molecule was effective in decreasing IGF-1 and GH levels and may serve as an effective therapeutic agent for acromegaly.

Citations

Citations to this article as recorded by  
  • Pituitary Tumorigenesis—Implications for Management
    Rodanthi Vamvoukaki, Maria Chrysoulaki, Grigoria Betsi, Paraskevi Xekouki
    Medicina.2023; 59(4): 812.     CrossRef
  • Current and Emerging Medical Therapies in Pituitary Tumors
    Nicolas Sahakian, Frédéric Castinetti, Thierry Brue, Thomas Cuny
    Journal of Clinical Medicine.2022; 11(4): 955.     CrossRef
  • Characterization of the ability of a, second-generation SST-DA chimeric molecule, TBR-065, to suppress GH secretion from human GH-secreting adenoma cells
    Thomas Cuny, Thomas Graillon, Célines Defilles, Rakesh Datta, Shengwen Zhang, Dominique Figarella-Branger, Henry Dufour, Grégory Mougel, Thierry Brue, Tanya Landsman, Heather A. Halem, Michael D. Culler, Anne Barlier, Alexandru Saveanu
    Pituitary.2021; 24(3): 351.     CrossRef
  • Efficacy of a Novel Second-Generation Somatostatin-Dopamine Chimera (TBR-065) in Human Medullary Thyroid Cancer: A Preclinical Study
    Alessandra Dicitore, Maria Celeste Cantone, Germano Gaudenzi, Davide Saronni, Silvia Carra, Maria Orietta Borghi, Manuela Albertelli, Diego Ferone, Leo J. Hofland, Luca Persani, Giovanni Vitale
    Neuroendocrinology.2021; 111(10): 937.     CrossRef
  • Emerging drugs for the treatment of acromegaly
    Claudia Campana, Giuliana Corica, Federica Nista, Francesco Cocchiara, Giulia Graziani, Keyvan Khorrami, Marta Franco, Mara Boschetti, Diego Ferone, Federico Gatto
    Expert Opinion on Emerging Drugs.2020; 25(4): 409.     CrossRef
Close layer
Review Article
Thyroid
Unmet Clinical Needs in the Treatment of Patients with Thyroid Cancer
Won Bae Kim, Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong
Endocrinol Metab. 2020;35(1):14-25.   Published online March 19, 2020
DOI: https://doi.org/10.3803/EnM.2020.35.1.14
  • 7,359 View
  • 140 Download
  • 15 Web of Science
  • 11 Crossref
AbstractAbstract PDFPubReader   ePub   

The increased incidence of thyroid cancer is a worldwide phenomenon; however, the issue of overdiagnosis has been most prominent in South Korea. The age-standardized mortality rate of thyroid cancer in Korea steeply increased from 1985 to 2004 (from 0.17 per 100,000 to 0.85 per 100,000), and then decreased until 2015 to 0.42 per 100,000, suggesting that early detection reduced mortality. However, early detection of thyroid cancer may be cost-ineffective, considering its very high prevalence and indolent course. Therefore, risk stratification and tailored management are vitally important, but many prognostic markers can only be evaluated postoperatively. Discovery of preoperative marker(s), especially for small cancers, is the most important unmet clinical need for thyroid cancer. Herein, we discuss some such factors that we recently discovered. Another unmet clinical need is better treatment of radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC) and undifferentiated cancers. Although sorafenib and lenvatinib are available, better drugs are needed. We found that phosphoglycerate dehydrogenase, a critical enzyme for serine biosynthesis, could be a novel therapeutic target, and that the lymphocyte-to-monocyte ratio is a prognostic marker of survival in patients with anaplastic thyroid carcinoma or RAIR DTC. Deeper insights are needed into tumor-host interactions in thyroid cancer to improve treatment.

Citations

Citations to this article as recorded by  
  • Macrophage-Induced Carboxypeptidase A4 Promotes the Progression of Anaplastic Thyroid Cancer
    Yeon-Sook Choi, Min Ji Jeon, Woo Kyung Lee Doolittle, Dong Eun Song, Kyunggon Kim, Won Bae Kim, Won Gu Kim
    Thyroid®.2024;[Epub]     CrossRef
  • Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study
    Mijin Kim, Meihua Jin, Min Ji Jeon, Eui Young Kim, Dong Yeob Shin, Dong Jun Lim, Bo Hyun Kim, Ho-Cheol Kang, Won Bae Kim, Young Kee Shong, Hee Kyung Kim, Won Gu Kim
    Thyroid.2023; 33(1): 91.     CrossRef
  • Serum thyroglobulin testing after thyroid lobectomy in patients with 1–4 cm papillary thyroid carcinoma
    Ahreum Jang, Meihua Jin, Chae A Kim, Min Ji Jeon, Yu-Mi Lee, Tae-Yon Sung, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Won Gu Kim
    Endocrine.2023; 81(2): 290.     CrossRef
  • Integration of ultrasound-based radiomics with clinical features for predicting cervical lymph node metastasis in postoperative patients with differentiated thyroid carcinoma
    Fengjing Fan, Fei Li, Yixuan Wang, Zhengjun Dai, Yuyang Lin, Lin Liao, Bei Wang, Hongjun Sun
    Endocrine.2023;[Epub]     CrossRef
  • Transcriptomic Analysis of Papillary Thyroid Cancer: A Focus on Immune-Subtyping, Oncogenic Fusion, and Recurrence
    Seung-Jin Park, Yea Eun Kang, Jeong-Hwan Kim, Jong-Lyul Park, Seon-Kyu Kim, Seung-Woo Baek, In Sun Chu, Shinae Yi, Seong Eun Lee, Young Joo Park, Eun-Jae Chung, Jin Man Kim, Hye Mi Ko, Je-Ryong Kim, Seung-Nam Jung, Ho-Ryun Won, Jae Won Chang, Bon Seok Koo
    Clinical and Experimental Otorhinolaryngology.2022; 15(2): 183.     CrossRef
  • Prognosis of Patients with 1–4 cm Papillary Thyroid Cancer Who Underwent Lobectomy: Focus on Gross Extrathyroidal Extension Invading Only the Strap Muscles
    Ahreum Jang, Meihua Jin, Won Woong Kim, Min Ji Jeon, Tae-Yon Sung, Dong Eun Song, Tae Yong Kim, Ki-Wook Chung, Won Bae Kim, Young Kee Shong, Yu-Mi Lee, Won Gu Kim
    Annals of Surgical Oncology.2022; 29(12): 7835.     CrossRef
  • Carboxy terminus of HSP70‐interacting protein (CHIP) attenuates the stemness of thyroid cancer cells through decreasing OCT4 protein stability
    Ying Xu, Gang Xu, Huimin Dang, Wei Qu, Dan Chang, Xin He, Minmin Li, Qian Wang
    Environmental Toxicology.2021; 36(4): 686.     CrossRef
  • Lactate Dehydrogenase A as a Potential New Biomarker for Thyroid Cancer
    Eun Jeong Ban, Daham Kim, Jin Kyong Kim, Sang-Wook Kang, Jandee Lee, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung, Kunhong Kim
    Endocrinology and Metabolism.2021; 36(1): 96.     CrossRef
  • Clinical implications of age and excellent response to therapy in patients with high‐risk differentiated thyroid carcinoma
    Meihua Jin, Jonghwa Ahn, Yu‐Mi Lee, Tae‐Yon Sung, Dong Eun Song, Tae Yong Kim, Ki‐Wook Chung, Jin‐Sook Ryu, Won Bae Kim, Young Kee Shong, Min Ji Jeon, Won Gu Kim
    Clinical Endocrinology.2021; 95(6): 882.     CrossRef
  • CD73 Overexpression Promotes Progression and Recurrence of Papillary Thyroid Carcinoma
    Young Mun Jeong, Haejin Cho, Tae-Min Kim, Yourha Kim, Sora Jeon, Andrey Bychkov, Chan Kwon Jung
    Cancers.2020; 12(10): 3042.     CrossRef
  • The Role of Exosomes in Thyroid Cancer and Their Potential Clinical Application
    Kaixiang Feng, Runsheng Ma, Lele Zhang, Hongqiang Li, Yifeng Tang, Gongbo Du, Dongpeng Niu, Detao Yin
    Frontiers in Oncology.2020;[Epub]     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism